Clinical trials: Unresectable Locally Advanced Cancer
Gastric Cancer
DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
This study evaluates the therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) combined with S-1 ((Tegafur, Gimeracil, and Oteracil Potassium) and oxaliplatin adjuvant…
- Trial name
- NCT02504229
- Testing
- autologous dendritic cells co-cultured with cytokine-induced killer cells, Gimeracil and Oteracil Porassium Capsules, Oxaliplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan (ABBV-400) is…
- Conditions
- Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- AndroMETa-GEA (NCT06628310)
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Fluorouracil
- Where
- 49 sites in United States, Belgium and 9 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Squamous Cell Carcinoma of the Head and Neck
Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC
Phase II trial evaluating to assess the feasibility and efficacy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC of Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in…
- Trial name
- DURTRE-RAD (NCT03624231)
- Testing
- Durvalumab, Tremelimumab, Radiotherapy
- Where
- 3 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Ulrich Keilholz
Pancreatic Cancer
Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer
The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK) for unresectable locally advanced pancreatic cancer.
- Trial name
- NCT01781520
- Testing
- DC-CIK Treatment, S1, Best supportive care
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Capital Medical University
IRE
IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
This is a prospective, randomized, controlled, exploratory Phase II clinical study. Approximately 60 eligible patients with locally advanced pancreatic cancer who have received three cycles of chemotherapy induction and have…
- Trial name
- NCT07799935
- Testing
- IRE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Malignant Neoplasm
First-in-Human Study of KO-947 in Non-Hematological Malignancies
This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological…
- Trial name
- NCT03051035
- Testing
- KO-947
- Where
- 5 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Kura Oncology, Inc.
Pancreatic Cancer Metastatic
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
This study is an Ib/II phase clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a second-line treatment for unresectable locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT07342725
- Testing
- IBI363 + chemotherapy
- Volunteers
- 48 people
- Sponsor
- Ruijin Hospital
HER2-positive Gastric Cancer
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive…
- Trial name
- NCT07332533
- Testing
- KN026, Capecitabine, Enlonstobart
- Volunteers
- 490 people
- Sponsor
- Shanghai JMT-Bio Inc.
Hepatocellular Carcinoma
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
The purpose of this study is to investigate the efficacy and safety of Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses.
- Trial name
- NCT05897138
- Testing
- Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Stage III Non-small Cell Lung Cancer
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy (CRT) is the current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) as it improves…
- Trial name
- NCT04984148
- Testing
- CT
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Guangdong Provincial People's Hospital
Pancreatic Cancer
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether nitrocamptothecin is more effective than gemcitabine for pancreatic cancer.
- Trial name
- NCT00005869
- Testing
- gemcitabine hydrochloride, rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Pancreatic Carcinoma Non-resectable, Metastatic Pancreatic Cancer
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
People with pancreatic cancer usually have a large amount of the cancer in the area of the pancreas and around it when they are diagnosed with it.
- Trial name
- NCT00761345
- Testing
- gemcitabine, Erlotinib, low dose fractionated radiotherapy
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Fox Chase Cancer Center
Stage III Non-small Cell Lung Cancer, Unresectable
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents.
- Trial name
- COAST (NCT03822351)
- Testing
- Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab
- Where
- 73 sites in United States, Canada and 7 more
- Volunteers
- 189 people
- Sponsor
- MedImmune LLC
Colorectal Cancer
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077337
- Testing
- romidepsin
- Where
- 88 sites in United States
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00005838
- Testing
- shark cartilage extract AE-941, cisplatin, vinorelbine tartrate
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- National Cancer Institute (NCI)
Solitary Fibrous Tumor, Extraskeletal Myxoid Chondrosarcoma
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
Phase II, open-label, non-randomized, international multicenter clinical trial with two strata (SFT and EMC). 8 sites in Spain, 5 sites in Italy and 5 sites in France.
- Trial name
- NCT02066285
- Testing
- Pazopanib
- Where
- 7 sites in Spain
- Volunteers
- 96 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine
Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
The aim of this clinical trial is to evaluate the efficacy and safety of consolidation therapy with a neoantigen-loaded dendritic cell vaccine (NeoDC-Vac) following radical chemoradiotherapy or chemoradiation-immunotherapy in…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Neoantigen-loaded Dendritic Cell Vaccine, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06675201
- Testing
- neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Sichuan University
Breast Cancer
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive…
- Trial name
- AMBITION (NCT04732598)
- Testing
- Paclitaxel + bevacizumab therapy, Paclitaxel + bevacizumab + atezolizumab
- Where
- Japan
- Volunteers
- 281 people
- Sponsor
- Japanese Foundation for Cancer Research
Carcinoma, Hepatocellular, Hepatocellular Cancer
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that…
- Conditions
- Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07227012
- Testing
- PF-08634404, Ipilimumab
- Where
- 60 sites in United States, China and 3 more
- Volunteers
- 138 people
- Sponsor
- Pfizer
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.